Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Glasdegib + Decitabine in Poor-Risk AML
NCT04051996Phase 2Terminated
- Sponsor
- Yale University
- Start
- Dec 2019
- Primary completion
- Jun 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of glasdegib in acute myeloid leukemia (AML), sponsored by Yale University. Started Dec 2019; status: terminated.
02
Drugs
glasdegib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT04051996.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04051996.